Cenix Prepares to Establish Belgian Subsidiary | GenomeWeb

Cenix BioScience this week announced that it will establish a new subsidiary to accelerate the firm's research and development capabilities in areas such as central nervous system-focused drug discovery and in vivo RNAi.

The subsidiary will be based in Belgium and reflects "a major growth and diversification initiative ongoing since 2008 to broaden the company's range of activities beyond [its core] cell-based RNAi services," Dresden, Germany-based Cenix said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.